Tablet Coating Market to exceed USD 1.4 billion by 2032, Says Graphical Research Powered by GMI
June 13, 2023 20:00 ET
|
Graphical Research
Selbyville, Delaware, June 13, 2023 (GLOBE NEWSWIRE) -- Tablet Coating Market size is estimated to surpass USD 1.4 billion by 2032. The increasing adoption of orphan drugs and medications...
Osteo-Pharma and Emultech Announce Joint Venture to Develop First-in-Class Disease-Modifying Treatment for Osteoarthritis
November 17, 2021 06:00 ET
|
Bone-Tech
AMSTERDAM, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Emultech and Osteo-Pharma today announced a joint venture, Bone-Tech, to develop what could be the first disease-modifying treatment for osteoarthritis...
Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs
March 27, 2014 12:15 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 27, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that it has created the position of Vice President, Quality...
Elite Pharmaceuticals, Inc. to Host Third Quarter Business Update Call on February 18, 2014
February 10, 2014 15:26 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and...
Elite Pharmaceuticals Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
September 03, 2013 09:46 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global...
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2014
August 14, 2013 16:29 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 14, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant...
Elite Pharmaceuticals, Inc. Hires Industry Veteran Doug Plassche as Executive Vice President of Operations
August 12, 2013 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 12, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP) today announced the appointment of industry veteran Doug Plassche as Executive Vice President of Operations...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2013, FQ4/13 Revenues Highest in Corporate History
June 21, 2013 13:44 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 21, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant...
Elite Pharmaceuticals, Inc. Announces 2013 Fiscal Year End Conference Call on Monday, June 24, 2013
June 19, 2013 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 19, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and...
Elite Laboratories Files Citizen Petition With the FDA on Brompheniramine Maleate and Pseudoephedrine HCL Extended Release
June 10, 2013 13:54 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 10, 2013 (GLOBE NEWSWIRE) -- Elite Laboratories, a wholly owned subsidiary of Elite Pharmaceuticals, Inc. (collectively ""Elite" or the "Company") (OTCBB:ELTP) today announced...